Food Companies Rethink Menus For GLP-1 Users As Wegovy Weight Loss Pill Gets Approval

Food makers and restaurants adjust menus and products as GLP-1 drugs drive demand for high-protein foods and smaller portions ...

Novo Nordisk oral weight loss pill made in NC to be available in January following FDA approval

On Monday, pharmaceutical company Novo Nordisk said its oral weight loss pill produced in North Carolina has been approved by the United States Food and Drug Administration and will be available ...

FDA approves Wegovy pill for weight loss: What to know

The Food and Drug Administration has approved the first GLP-1 pill for weight loss and maintenance. Drugmaker Novo Nordisk ...
STAT

Novo Nordisk’s semaglutide fails to slow Alzheimer’s progression

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Elaine Chen covers biotech, co-writes The Readout newsletter, and ...
CNN

Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, drugmaker Novo Nordisk ...
Reuters

China's Innovent says its GLP-1 works better than Novo's semaglutide in diabetes study

SHANGHAI, Oct 27 (Reuters) - China's Innovent Biologics (1801.HK), opens new tab said, opens new tabon Monday its GLP-1 injection led to more weight loss and better control of blood sugar in patients ...
TCTMD

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Oral semaglutide (Rybelsus) can now be used to reduce major adverse cardiovascular events in patients with type 2 diabetes and high cardiovascular risk, following the US Food and Drug Administration’s ...
Today

Is Ozempic or Wegovy Safe for Weight Loss While Breastfeeding? What Doctors Say

Pregnancy and semaglutide — the active ingredient in GLP-1 drugs such as Ozempic for Type 2 diabetes and Wegovy for weight loss — don’t mix. But what about breastfeeding? Women should stop taking ...
The American Journal of Managed Care

FDA Expands Semaglutide Label to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes

Oral semaglutide is now approved to reduce cardiovascular risk in high-risk type 2 diabetes patients, marking a first for oral GLP-1 receptor agonists. The SOUL trial showed a 14% relative risk ...
Medscape

Semaglutide, Tirzepatide Named First-Line Drugs for Obesity

Semaglutide or tirzepatide should be first-line drugs for obesity and most of its related complications, new guidance from the European Association for the Study of Obesity recommended. The authors of ...
Science Daily

This new semaglutide dose helped nearly half of patients lose 20% body weight

The STEP UP trials revealed that a 7.2 mg dose of semaglutide led to greater weight loss than the currently approved 2.4 mg dose. Nearly half of participants lost 20% or more of their body weight, ...
BioSpace

Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study

“The oral semaglutide 25 mg data show compelling efficacy for an oral weight management medication with 16.6% weight loss and a safety and tolerability profile consistent with injectable Wegovy ®,” ...